These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26349221)

  • 1. [Investigation of the Influence of Angiogenesis on Tumor Growth with the Use of a Mathematical Model].
    Kolobov AV; Kuznetsov MB
    Biofizika; 2015; 60(3):555-63. PubMed ID: 26349221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mathematical model of angiogenesis and tumor growth: analysis and application in anti-angiogenesis therapy.
    Zheng X; Sweidan M
    J Math Biol; 2018 Nov; 77(5):1589-1622. PubMed ID: 30019238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
    Rak J; Yu JL
    Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.
    Bocci G; Loupakis F
    Pharmacogenomics; 2011 Aug; 12(8):1077-80. PubMed ID: 21843059
    [No Abstract]   [Full Text] [Related]  

  • 9. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
    Hlushchuk R; Makanya AN; Djonov V
    Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
    Sun ZJ; Chen G; Zhang W; Hu X; Huang CF; Wang YF; Jia J; Zhao YF
    J Pharmacol Exp Ther; 2010 Aug; 334(2):500-12. PubMed ID: 20484154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.
    Ye W
    Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.
    Wong ML; Prawira A; Kaye AH; Hovens CM
    J Clin Neurosci; 2009 Sep; 16(9):1119-30. PubMed ID: 19556134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pericytes: a double-edged sword in cancer therapy.
    Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
    Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.